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Running Head: Maintenance chemotherapy schedules for metastatic breast cancer 
 
Key message: The SNAP trial shows alternative maintenance chemotherapy schedules 
with single-agent nab-Paclitaxel at reduced doses after a short-term induction at 
conventional doses are feasible and active in first-line treatment of metastatic breast 
cancer. Quality-of-life scores for neuropathy showed minimal further decline during 
maintenance after the substantial and expected decline during induction therapy.  
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ABSTRACT  
Background: The phase II SNAP trial was designed to evaluate the efficacy of alternative 
chemotherapy schedules for prolonged administration in HER2-negative metastatic breast 
cancer (MBC), after a short induction at conventional doses.  
Methods: Between April 2013 and August 2015, 258 women untreated with chemotherapy 
for MBC were randomly assigned to receive three different maintenance chemotherapy 
schedules after three cycles of identical induction chemotherapy: Arm A, nab-Paclitaxel 
150 mg/m2 days 1,15 Q28; Arm B, nab-Paclitaxel 100 mg/m2 days 1,8,15 Q28; Arm C, 
nab-Paclitaxel 75 mg/m2 days 1,8,15,22 Q28. Induction was three cycles nab-Paclitaxel 
150/125 mg/m2, days 1,8,15 Q28. The primary objective was to evaluate the efficacy of 
each maintenance schedule, in terms of progression-free survival (PFS), as compared to 
the historical reference of 7-month median PFS reported by previous studies with first-line 
docetaxel. One-sample, one-sided log-rank tests were utilized. Quality-of-life evaluation 
was performed, global indicator for physical well-being was defined as the primary 
endpoint; completion rates of quality-of-life forms were >90%. 
Results: 255 patients were evaluable for the primary endpoint. After 18.2 months median 
follow-up, 182 PFS events were observed. Median PFS was 7.9 months (90%CI 6.8-8.4) 
in Arm A, 9.0 months (90%CI 8.1-10.9) in Arm B and 8.5 months (90%CI 6.7-9.5) in Arm 
C. PFS in Arm B was significantly longer than the historical reference of first-line docetaxel 
(P=0.03). Grade≥2 sensory neuropathy was reported in 37.9%, 36.1% and 31.2% of 
patients in Arm A, Arm B and Arm C, respectively (Grade≥3 in 9.1%, 5.6% and 6.6% of 
patients, respectively). Noteworthy, the quality-of-life scores for sensory neuropathy did 
not worsen with prolonged nab-Paclitaxel administration in any of the maintenance arms. 
Conclusion: The SNAP trial demonstrated that alternative nab-Paclitaxel maintenance 
schedules with reduced dosages after a short induction at conventional doses are feasible 
and active in the  first-line treatment of MBC. 
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INTRODUCTION  
Metastatic breast cancer (MBC) can be successfully managed for years [1-4] with 
appropriate treatments, aimed at prolonging survival with good quality-of-life (QoL) and 
symptom palliation. Virtually all MBC patients are candidate to chemotherapy, either 
upfront, or after failure of multiple lines of endocrine therapy. Whereas the selection of the 
most appropriate chemotherapy regimen is influenced by patient and disease-related 
factors as well as by patient/physician preferences, controversy remains about how long 
chemotherapy should be continued in the absence of disease progression, due to its long-
term impact on patient quality-of-life. 
 
In the past, several randomized clinical trials have addressed the issue of prolonged 
chemotherapy administration in MBC [5-16], comparing shorter with longer durations as 
first-line treatment. Most studies indicated that longer treatment results in an improved 
time to progression, but failed to consistently show a survival benefit. A systematic review, 
including 11 of these trials showed that prolonged chemotherapy was associated with a 
clinically-meaningful and statistically-significant improvement in progression-free survival  
and a moderate, but significant improvement in overall survival [17]. On the basis of these 
results, prolonged chemotherapy administration may now be justified, in light of an 
appreciable survival benefit for some patients [18]. However, in all trials, maintenance 
schedules were based on full therapeutic drug dosages, with a potential impact on quality-
of-life due to the prolonged chemotherapy exposure. In this perspective, the SNAP trial 
was designed to improve the efficacy and tolerability of prolonged chemotherapy 
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administration by studying alternative maintenance schedules  while preserving and 
possibly improving 
treatment efficacy in this disease setting. The availability of a new nanoparticle albumin-
bound taxane, nab-Paclitaxel, represented an opportunity to test this hypothesis, as this 
agent has been shown to reduce the toxicity associated with standard taxane 
administration, while increasing antitumor efficacy [19, 20].  
 
METHODS 
Study design and patients 
Trial IBCSG 42-12/BIG 2-12, SNAP (Schedules of nab-Paclitaxel), was a multicenter, 
randomized, phase II clinical trial assessing three alternative maintenance chemotherapy 
regimens using nab-Paclitaxel as first-line treatment in MBC. The IBCSG Ethics 
Committee and ethics committees at each participating institution and relevant health 
authorities approved the study protocol; all patients provided written informed consent. The 
IBCSG Data and Safety Monitoring Committee reviewed the trial twice-yearly. Eligible 
women were ≥18 years, with ECOG PS 0 or 1, and life-expectancy >3 months. Patients 
had stage IV MBC that was HER2-negative, estrogen receptor (ER)-negative or 
endocrine-resistant ER-positive (defined as having failed at least one prior endocrine 
therapy or candidate for first-line chemotherapy), and measurable or non-measurable 
according to RECIST 1.1 criteria. Prior adjuvant chemotherapy was allowed, provided it 
stopped ≥12 months before enrollment. 
 
Randomization procedures 
Eligible women were randomly assigned (1:1:1) to three alternative schedules of nab-
Paclitaxel (Abraxane®, Celgene) (Figure 1). Each treatment arm included an induction 
phase consisting of three nab-Paclitaxel cycles at conventional dosages and a 
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maintenance phase as follows: Arm A, nab-Paclitaxel 150 mg/m2 days 1,15 Q28; Arm B, 
nab-Paclitaxel 100 mg/m2 days 1,8,15 Q28; Arm C, 75 mg/m2 days 1,8,15,22, Q28. In the 
original study design, the induction phase consisted of nab-Paclitaxel 150 mg/m2 days 
1,8,15 Q28, but was modified to 125 mg/m2 days 1,8,15 Q28 following a safety review of 
the first 48 treated patients. Treatment was administered until progressive disease, 
unacceptable toxicity or patient refusal. 
 
Study Procedures 
Patients were monitored with physical exam, biochemistry and hematology, and evaluated 
for disease response according to RECIST version 1.1 at baseline and every 12 weeks 
until documented progression, even after treatment discontinuation for reason other than 
progression. Targeted adverse events were reported for each cycle and graded according 
to CTCAE v4.0.  
 
Endpoints 
The primary endpoint was progression-free survival (PFS), defined as time from 
randomization to disease progression or death from any cause, provided death occurred 
within 12 weeks following the last disease assessment; otherwise the endpoint was 
censored at date of last progression-free assessment. Secondary endpoints included 
tolerability (adverse events), feasibility (completion of treatment per protocol for ≥24 
weeks), best overall response according to RECIST 1.1, overall survival (OS; time time 
from randomization to death from any cause; otherwise censored at date last known alive), 
and QoL.  
 
Statistical Considerations 
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PFS distributions were estimated by Kaplan-Meier method and two-sided 90% confidence 
interval (CI) for the median PFS was provided based on complementary log-log 
transformation. PFS of each treatment arm was compared to an historical-control PFS of 
first-line docetaxel using a one-sample, one-sided (α=0.05) log-rank test without 
adjustment for multiple tests. An historical reference of 7-month median PFS was selected 
based on the most recent trial with a docetaxel control arm [19]. Seventy-six patients (63 
PFS events) per arm, and accrual of 8 patients per month over 30 months plus 12 months 
additional follow-up, provided 88% power to detect an improvement in median PFS from 7 
to 10 months. The final sample size was 86 patients per arm, assuming 12% drop-out 
without documented PFS event. Secondary endpoints were summarized descriptively. 
 
Quality of Life  (QoL) 
Patients completed a paper-based QoL assessment at baseline (prior to randomization), 
and day 1 of each of the first 12 cycles, unless treatment discontinued earlier. Forms were 
completed before any diagnostic procedures (exception: baseline) or treatment 
administration. The assessment consisted of global indicators for physical well-being, 
which was defined as the primary QoL endpoint, mood, coping effort, overall treatment 
burden, and symptom-specific indicators for appetite, tiredness, hair loss and feeling sick 
(nausea/vomiting) based on the GLQ-8. All indicators were in linear analogue self-
assessment (LASA) format ranging 0-100. A clinically-significant change was 
conservatively defined as at least ±8 points. Sensory neuropathy was assessed by 4-item 
subscale of the FACT/GOG-Ntx with a 5-point response format (“not at all” to “very much”, 
score ranging 0-16). Scores of all indicators were linearly transformed to range from 0-100 
with higher numbers reflecting a better condition. 
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The changes in QoL scores from baseline to day 1 of cycle 4 (after the three induction 
cycles), and from day 1 of cycle 4 to day 1 of cycle 12 were summarized descriptively. 
Treatment effects on changes in QoL score during maintenance therapy were analyzed by 
repeated measures modeling, including timepoint (cycle), induction dose, age, and 
treatment arm as covariates.  
 
RESULTS 
The SNAP trial enrolled 258 patients in 35 centers in six countries from April 2013 to 
August 2015; 255 patients initiated treatment and were considered evaluable (Figure 1).  
Patient and disease characteristics were balanced between the three groups (Table 1). 
The median age at randomization was 58 years (range, 27 to 85). ECOG PS was 0 in 
63.5% of patients. Approximately three-quarters of the patients had ER-positive tumors 
(82.9%), 210 (82.4%) had measurable disease and 184 patients (72.2%) had visceral 
involvement. Prior adjuvant taxane was administered in 80 patients (31.4%).  
 
Efficacy 
After median follow-up of 18.2 months (range, <1-36 months), 182 PFS events were 
documented. The median PFS was 7.9 months (90%CI 6.8-8.4) in Arm A, 9.0 months 
(90%CI 8.1-10.9) in Arm B, and 8.5 months (90%CI 6.7-9.5) in Arm C (Figure 2). PFS 
observed in Arm B was significantly longer than the historical reference of median 7 
months reported with first line docetaxel (one-sided log-rank P=0.03). Eighty-five patients 
died. The median OS was 25.8 months (90%CI 16.9-infinity) in Arm A, 26.2 months 
(90%CI 21.0-infinity) in Arm B and 25.5 months (90%CI 22.7-infinity) in Arm C (Figure 
S1).  
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Complete response occurred in 15 patients; 5 (6.0%), 6 (7.0%) and 4 (4.7%) in Arms A, B 
and C, respectively; and partial response in 110 patients; 34 (41.0%), 41 (47.7%) and 35 
(40.7%) in Arms A, B and C. Stable disease was observed in 103 patients; 39 (47.0%) in 
Arm A, 33 (38.4%) in Arm B and 31 (36%) in Arm C. Clinical benefit, defined as duration of 
stable disease ≥24 weeks or partial or complete response, were observed in 165 patients; 
54 (65.1%), 59 (68.6%), and 52 (60.5%) for Arms A, B, C respectively. 
 
Feasibility and Adverse Events 
Feasibility, defined as completing induction and maintenance treatment according to 
protocol for ≥24 weeks, was 48.2% (90%CI 38.7-57.8%), 50.0% (90%CI 40.7-59.3%), and 
51.2% (90%CI 41.8-60.5%) for Arms A, B, C respectively. 
 
In the induction phase, 122 and 133 patients received nab-Paclitaxel at the starting dose 
of 150 mg/m² and 125 mg/m2, respectively. Overall, 227/255 (89%) patients completed 3 
cycles of induction treatment: their median relative dose-intensity was 86.1% with the nab-
Paclitaxel 150 mg/m² and 93.3% with the 125 mg/m² dose. At least one AE occurred in 
244/255 patients (95.7%; Table 2): 120/122 (98.4%) at the nab-Paclitaxel 150 mg/m² and 
124/133 (93.2%) at the 125 mg/m² dose. Grade ≥2 peripheral sensory neuropathy was 
reported in 14.8% (90%CI 9.8-21.1%) of patients treated with the 150 mg/m² dose and 
7.5% (90%CI 4.1-12.4%) with 125 mg/m². Grade ≥3 peripheral sensory neuropathy 
occurred in 2.5% (90%CI 0.7-6.2%) and in 0% (90% CI 0-2.2%) of patients, respectively.  
 
One hundred ninety-nine patients started maintenance treatment. Grade ≥2 peripheral 
sensory neuropathy was reported in 37.9% (90%CI 27.9-48.7%) of patients in Arm A, 
36.1% (90%CI 26.7-46.4%) in Arm B and 31.2% (90%CI 21.5-42.3%) in Arm C. Grade ≥3 
was reported for 9.1% (90%CI 4.0-17.2%), 5.6% (90%CI 1.9-12.3%) and 6.6% (90%CI 
Downloaded from https://academic.oup.com/annonc/advance-article-abstract/doi/10.1093/annonc/mdx772/4710349
by E-Library Insel user
on 08 February 2018
10 
 
2.3-14.4%) of patients, respectively (Figure S2). Dose reductions/delays due to peripheral 
sensory neuropathy occurred in 21.2%, 11.1% and 11.4% of patients, respectively, in 
Arms A, B and C.  
 
Quality-of-Life  
Completion rates of QoL forms were >90% through the cycle 12 assessment and were 
similar between treatment arms. At baseline, patients reported low scores for tiredness 
(mean±SD in Arm A 56.6±28.6; Arm B 57.0±29.7; Arm C 53.8±29.7), physical well-being 
(Arm A 66.3±27.5; Arm B 69.0±29.1; Arm C 63.3±27.7), mood (Arm A 64.0±27.3; Arm B 
64.4±27.1; Arm C 53.4±28.4), and coping effort (Arm A 56.7±31.8; Arm B 61.7±29.0; Arm 
C 44.3±31.8) indicating impaired QoL before starting treatment (Table S1). During the 
induction phase (baseline to day 1 of cycle 4) hair loss (mean±SD of change in Arm 
A -70.2±41.9; Arm B -77.3±34.5; Arm C -72.6±32.8), and sensory neuropathy (Arm 
A -19.0±25.2; Arm B -20.6±22.7; Arm C -18.8±23.8), showed the most pronounced 
worsening in symptoms and treatment burden was substantially impaired (Table S2). 
 
Figure 3 summarizes changes in QoL scores  during the maintenance phase. Hair loss 
significantly improved during maintenance therapy, with patients in Arms B (18.6; 95%CI 
7.5-29.6; P=0.001) and C (mean difference 10.9; 95%CI 0.4-21.5; P=0.04) reporting a 
greater improvement compared to those in Arm A. Noteworthy, the scores for sensory 
neuropathy did not worsen with prolonged nab-Paclitaxel administration in any of the 
maintenance arms. There were also no significant differences in changes for the other 
symptoms. Patients in Arm C reported a significantly greater improvement in mood 
compared to Arm A (mean difference 13.3; 95%CI 6.1-20.6; P<0.001) and Arm B (mean 
difference 9.6; 95%CI 2.8-16.4; P=0.01)]. There were no significant differences in changes 
for the other global indicators.  
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DISCUSSION 
The SNAP trial shows that in the first-line treatment of MBC, a chemotherapy maintenance 
schedule with single-agent nab-Paclitaxel at reduced doses, after a short-term induction at 
conventional doses, is feasible and more active than the historical data available with 
docetaxel single-agent. In particular, median PFS in Arm B, with a dose de-escalation from 
150/125 to 100 mg/m² days 1,8,15 Q28, was significantly longer than the historical PFS of 
docetaxel (PFS 9.0 versus 7.0 months, P=0.03). This result needs to be interpreted with 
caution, due to the lack of a prospective comparison with a docetaxel single-agent control 
arm. However, these data must be weighted taking into account that all  major guidelines 
recommend to prolong chemotherapy until disease progression [1,18], with a non 
negligible impact on patient tolerability in the setting of incurable disease. This 
recommendation is based on the results of clinical trials comparing different chemotherapy 
durations at full therapeutic doses. In this perspective, the results of the SNAP trial indicate 
that prolonged administration of nab-Paclitaxel at reduced doses may represent an 
innovative treatment strategy to improve the outcome of MBC patients, while preserving 
patients’ QoL. 
 
As expected, neurotoxicity was the most frequent adverse event, reported in about one-
third of the patients during the maintenance phase. Indeed, in the Gradishar et al study 
[19], comparing three different nab-Paclitaxel schedules with docetaxel in MBC,  the 
incidence of sensory neuropathy was similar, with a shorter time to recovery (from grade 3 
to grade <2) in the nab-Paclitaxel arm. Noteworthy, in the SNAP QoL study, after the 
substantial and expected deterioration in neurotoxicity during induction, there was a 
marginal change with prolonged chemotherapy administration. Furthermore, patients 
reported improvements in their perception of hair loss and in mood during maintenance 
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therapy, particularly in Arms B and C. For some of the other QoL domains a similar 
tendency was seen. These data further support the concept that prolonged chemotherapy 
administration in responding patients is not associated with a deterioration in QoL, thus 
confirming and confirm the QoL data already reported by two of the published studies on 
maintenance chemotherapy [5,21,22]. The QoL analysis of the SNAP trial, together with 
the PFS data obtained in  Arm B, support the use of reduced nab-Paclitaxel doses during 
the maintenance phase, considering its favorable impact on QoL and the palliative intent in 
this advanced disease stage.  
 
A limitation of our trial is the absence of a direct comparison with a standard-dose 
prolonged chemotherapy arm, as patient selection may have led to a longer PFS than the 
historical control, but is mitigated by having three investigational arms. A trial design to 
include a fourth control arm for direct comparison would have required about 150 patients 
per arm, accrual to which would be vey difficult in view of emerging results with new 
biological compounds.  
 
In conclusion, the SNAP trial was the first trial of prolonged chemotherapy administration 
that evaluated de-escalation of a chemotherapeutic agent, nab-Paclitaxel as maintenance 
treatment in HER2 negative MBC patients. Its results indicate that an alternative 
maintenance nab-Paclitaxel schedule, with reduced doses after a short-term induction 
chemotherapy at conventional doses, is feasible and resulted in a median PFS 
significantly greater than the historical reference of 7.0 months achieved with conventional 
docetaxel. The QoL analysis of the SNAP trial, together with the PFS data, support the use 
of nab-Paclitaxel at reduced doses (100 mg/m2 days 1,8,15 Q28) as maintenance 
following a short induction at full therapeutic dosages.  
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FIGURE LEGENDS 
Figure 1. IBCSG 42-12/BIG 2-12 SNAP (Schedules of nab-Paclitaxel) schema and 
CONSORT flow diagram. 
 
Figure 2. Kaplan-Meier estimates of progression-free survival (PFS) according to 
treatment arm. 
 
Figure 3. Changes in quality-of-life scores from day 1 of cycle 4 (after completion of 3 
induction treatment cycles, prior to initiating maintenance phase) according to the 
maintenance schedule of nab-Paclitaxel administration for cycles 6, 9, and 12. Data are 
summarized as mean with 95% CI. 
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Figure 2. Kaplan-Meier estimates of progression-free survival (PFS) according to treatment arm  
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Figure 3. Changes in quality-of-life scores from day 1 of cycle 4 (after completion of 3 induction treatment 
cycles, prior to initiating maintenance phase) according to the maintenance schedule of nab-Paclitaxel 
administration for cycles 6, 9, and 12. Data are summarized as mean with 95% CI  
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Table 1. Patient, disease and prior treatment characteristics of 255 patients in the SNAP 
trial. 
 
Arm A 
(N=83) 
Arm B 
(N=86) 
Arm C 
(N=86) 
Total 
(N=255) 
Age (yrs), median (range) 58 (35, 85) 56 (27, 83) 60 (38, 83) 58 (27, 85) 
    < 70 years 74 (89.2 %) 74 (86.0%) 72 (83.7%) 220 (86.3%) 
     ≥70 years 9 (10.8%) 12 (14.0%) 14 (16.3%) 35 (13.7%) 
Body mass index (kg/m2)     
    <25 41 (49.4%) 43 (50.0%) 33 (38.4%) 117 (45.9%) 
    ≥ 25 and <30 18 (21.7%) 22 (25.6%) 31 (36.0%) 71 (27.8%) 
    ≥30 24 (28.9%) 21 (24.4%) 22 (25.6%) 67 (26.3%) 
ECOG PS  0 (cycle 1 day 1) 49 (59.0%) 59 (68.6%) 55 (64.0%) 163 (63.9%) 
De novo stage IV MBC 27 (32.5%) 17 (19.8%) 24 (27.9%) 68 (26.7%) 
ER positive* 72 (86.7%) 69 (80.2%) 69 (80.2%) 210 (82.4%) 
PgR positive* 56 (67.5%) 62 (72.1%) 62 (72.1%) 180 (70.6%) 
Measurable disease 68 (81.9%) 73 (84.9%) 69 (80.2%) 210 (82.4%) 
Dominant metastatic site viscera 53 (63.9%) 66 (76.7%) 65 (75.6%) 184 (72.2%) 
Number of metastatic sites      
    ≤ 3 74 (89.2%) 71 (82.6%) 70 (81.4%) 215 (84.3%) 
    > 3 9 (10.8%) 15 (17.4%) 16 (18.6%) 40 (15.7%) 
Prior adjuvant chemotherapy 44 (53.0%) 53 (61.6%) 41 (47.7%) 138 (54.1%) 
Prior adjuvant taxane 26 (31.3%) 28 (32.6%) 26 (30.2%) 80 (31.4%) 
Prior adjuvant endocrine therapy 42 (50.6%) 56 (65.1%) 54 (62.8%) 152 (59.6%) 
Prior endocrine therapy for metastatic disease 30 (36.1%) 30 (34.9%) 33 (38.4%) 93 (36.5%) 
Abbreviations: ECOG PS=Eastern Cooperative Oncology Group Performance Status; ER=estrogen 
receptor; MBC=metastatic breast cancer; PgR=progesterone receptor 
* On basis of metastatsis, if available, otherwise primary tumor 
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Table 2. Adverse events (maximum grade) reported among 255 patients initiating the induction phase and 199 patients who 
initiated the maintenance phase of the SNAP trial. Data are % of patients. 
Adverse Event 
(CTCAE v4.0) 
Induction Phase 
All Arms 
N=255 
 Maintenance Phase 
Arm A 
N=66 
Arm B 
N=72 
Arm C 
N=61 
 Grade  Grade 
 
1 2 3 4  1 2 3 4 1 2 3 4 1 2 3 4 
Peripheral sensory neuropathy 40.8 9.8 1.2 0  39.4 28.8 9.1 0 37.5 30.6 5.6 0 45.9 24.6 6.6 0 
Neutropenia 6.7 32.5 19.2 3.9  12.1 15.2 4.5 1.5 11.1 23.6 8.3 0 16.4 21.3 6.6 0 
Decreased platelets 7.1 0 0 0.4  3.0 0 0 0 2.8 1.4 0 0 3.3 0 0 0 
Febrile neutropenia - - 1.2 0  - - 0 0 - - 1.4 0 - - 0 0 
Anemia 33.3 23.9 2.0 0  45.5 9.1 0 0 44.4 18.1 2.8 0 49.2 9.8 0 0 
Nausea 27.1 5.9 0.8 -  21.2 4.5 1.5 - 18.1 2.8 0 - 26.2 3.3 1.6 - 
Vomiting 7.8 1.6 1.2 0  7.6 0 1.5 0 6.9 2.8 0 0 13.1 1.6 1.6 0 
Diarrhea 20.0 4.3 3.5 0  10.6 0 3.0 0 12.5 2.8 1.4 0 13.1 6.6 0 0 
Allergic reaction 4.3 0.8 0 0  6.1 0 0 0 1.4 1.4 0 0 3.3 0 0 0 
Pneumonitis 0.4 1.2 0 0  0 0 0 0 1.4 1.4 0 0 0 4.9 0 0 
Total patients with ≥1 AE* 95.7  95.5 95.8 96.7 
 
 Dash (-) indicates the grade is not relevant for the AE 
* Includes reports of other grade 3-5 AEs (data not shown)   
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